4.7 Article

A novel Fizzy/Cdc20-dependent mechanism suppresses necrosis in neural stem cells

Journal

DEVELOPMENT
Volume 141, Issue 7, Pages 1453-1464

Publisher

COMPANY BIOLOGISTS LTD
DOI: 10.1242/dev.104786

Keywords

Cdc20/Fizzy; Drosophila; Brain; Catastrophic cellular stress; Necrosis; Neuroblast

Funding

  1. Minas Gerais State Research Council
  2. National Institutes of Science (NIH) Medical Scientist Training Program (MSTP) [T32-GM07863]
  3. University of Michigan
  4. Burroughs Wellcome Fund Career Award in the Biomedical Sciences [1006160.01]
  5. NIH [R01-GM092818]
  6. Sontag Foundation Distinguished Scientist Award

Ask authors/readers for more resources

Cancer stem cells likely survive chemotherapy or radiotherapy by acquiring mutations that inactivate the endogenous apoptotic machinery or by cycling slowly. Thus, knowledge about the mechanisms linking the activation of an alternative cell death modality and the cell cycle machinery could have a transformative impact on the development of new cancer therapies, but the mechanisms remain completely unknown. We investigated the regulation of alternative cell death in Drosophila larval brain neural stem cells (neuroblasts) in which apoptosis is normally repressed. From a screen, we identified two novel loss-of-function alleles of the Cdc20/fizzy (fzy) gene that lead to premature brain neuroblast loss without perturbing cell proliferation in other diploid cell types. Fzy is an evolutionarily conserved regulator of anaphase promoting complex/ cyclosome (APC/C). Neuroblasts carrying the novel fzy allele or exhibiting reduced APC/C function display hallmarks of necrosis. By contrast, neuroblasts overexpressing the non-degradable form of canonical APC/C substrates required for cell cycle progression undergo mitotic catastrophe. These data strongly suggest that Fzy can elicit a novel pro-survival function of APC/C by suppressing necrosis. Neuroblasts experiencing catastrophic cellular stress, or overexpressing p53, lose Fzy expression and undergo necrosis. Co-expression of fzy suppresses the death of these neuroblasts. Consequently, attenuation of the Fzydependent survival mechanism functions downstream of catastrophic cellular stress and p53 to eliminate neuroblasts by necrosis. Strategies that target the Fzy-dependent survival mechanism might lead to the discovery of new treatments or complement the pre-existing therapies to eliminate apoptosis-resistant cancer stem cells by necrosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Developmental Biology

miR-8 modulates cytoskeletal regulators to influence cell survival and epithelial organization in Drosophila wings

Kelsey Bolin, Nicholas Rachmaninoff, Kea Moncada, Katharine Pula, Jennifer. Kennell, Laura Buttitta

DEVELOPMENTAL BIOLOGY (2016)

Review Developmental Biology

States of G0 and the proliferation-quiescence decision in cells, tissues and during development

Dan Sun, Laura Buttitta

INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2017)

Article Genetics & Heredity

Chromatin organization changes during the establishment and maintenance of the postmitotic state

Yiqin Ma, Laura Buttitta

EPIGENETICS & CHROMATIN (2017)

Article Multidisciplinary Sciences

Anticancer polymers designed for killing dormant prostate cancer cells

Haruko Takahashi, Kenji Yumoto, Kazuma Yasuhara, Enrico T. Nadres, Yutaka Kikuchi, Russell S. Taichman, Kenichi Kuroda

SCIENTIFIC REPORTS (2019)

Article Endocrinology & Metabolism

Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer

Frank C. Cackowski, Yugang Wang, Joseph T. Decker, Christopher Sifuentes, Steven Weindorf, Younghun Jung, Yu Wang, Ann M. Decker, Kenji Yumoto, Nicholas Szerlip, Laura Buttitta, Kenneth J. Pienta, Todd M. Morgan, Russell S. Taichman

PROSTATE (2019)

Article Biochemistry & Molecular Biology

Changes in chromatin accessibility ensure robust cell cycle exit in terminally differentiated cells

Yiqin Ma, Daniel J. McKay, Laura Buttitta

PLOS BIOLOGY (2019)

Article Biology

Polyploidy in the adult Drosophila brain

Shyama Nandakumar, Olga Grushko, Laura A. Buttitta

ELIFE (2020)

Review Biochemistry & Molecular Biology

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside

Darleny Y. Lizardo, Chaoyuan Kuang, Suisui Hao, Jian Yu, Yi Huang, Lin Zhang

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)

Article Oncology

Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow

Younghun Jung, Frank C. Cackowski, Kenji Yumoto, Ann M. Decker, Yu Wang, Megan Hotchkin, Eunsohl Lee, Laura Buttitta, Russell S. Taichman

Summary: The study reveals that ABA can induce PCa cellular dormancy by regulating PPAR gamma receptor signaling and suppressing phosphorylation of mTOR/p70S6K signaling. ABA inhibits PCa cell proliferation and prolongs the G(0) cell cycle arrest.

NEOPLASIA (2021)

Article Multidisciplinary Sciences

The Kruppel-like factor Cabut has cell cycle regulatory properties similar to E2F1

Peng Zhang, Alexia J. Katzaroff, Laura A. Buttitta, Yiqin Ma, Huaqi Jiang, Derek W. Nickerson, Jan Inge Ovrebo, Bruce A. Edgar

Summary: The study identified Cabut as a positive regulator of cell cycle gene expression and cell proliferation, by regulating a large set of E2F1 target genes independently of E2F1. This finding suggests a distinct mechanism for cell cycle regulation with potential implications in normal and cancerous cell cycles.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Oncology

Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Chaoyuan Kuang, Yongseok Park, Ryan C. Augustin, Yan Lin, Douglas J. Hartman, Lindsey Seigh, Reetesh K. Pai, Weijing Sun, Nathan Bahary, James Ohr, John C. Rhee, Stanley M. Marks, H. Scott Beasley, Yongli Shuai, James G. Herman, Hassane M. Zarour, Edward Chu, James J. Lee, Anuradha Krishnamurthy

Summary: This study investigated the activity and tolerability of pembrolizumab plus azacitidine in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The combination therapy showed a modest clinical activity, with an overall response rate of 3%, a median progression-free survival of 1.9 months, and a median overall survival of 6.3 months. The demethylation of tumor DNA was associated with tumor-immune modulation.

CLINICAL EPIGENETICS (2022)

Article Biochemistry & Molecular Biology

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu

Summary: Mutant KRAS plays a crucial role in colorectal cancer by promoting Myc translation and Myc-dependent stress adaptation and proliferation. The combination of two FDA-approved drugs, Bortezomib and Everolimus, has been found to be highly effective against mutant KRAS colorectal cancer cells. This combination rapidly depletes Myc protein and induces cell death through various pathways. The study also shows that mutant KRAS colorectal cancer cells with elevated basal Myc and p-eIF2 alpha are more sensitive to the BR combination and exhibit characteristics of stress adaptation and cell death.

MOLECULAR BIOMEDICINE (2022)

Article Medicine, General & Internal

A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab

Chaoyuan Kuang, Kevin Quann, Agnes K. Liman, Roy Frye, Nawras Alshoubaki, Mohan Ramkumar, Andrew D. Liman

CLINICAL CASE REPORTS (2020)

Meeting Abstract Oncology

Biomarker analysis for UPCI 14-118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer

Chaoyuan Kuang, Yongseok Park, Nathan Bahary, Weijing Sun, James Ohr, John C. Rhee, Stanley M. Marks, H. Scott Beasley, Yongli Shuai, Yan Lin, Reetesh K. Pai, Anuradha Krishnamurthy, Hassane M. Zarour, James Herman, Edward Chu, James J. Lee

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Medicine, Research & Experimental

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer

Xiangping Song, Lin Shen, Jingshan Tong, Chaoyuan Kuang, Shan Zeng, Robert E. Schoen, Jian Yu, Haiping Pei, Lin Zhang

THERANOSTICS (2020)

No Data Available